Centro Ricerche Cliniche Di Verona S.r.l.

The Centro Ricerche Cliniche Di Verona Oncology department is engaged in a broad portfolio of cancer studies, emphasizing the testing of new targeted and immunotherapeutic approaches for advanced solid tumors.

• Metastatic non‑small cell lung cancer
• HER2‑positive gastric cancer
• Metastatic clear cell renal cell carcinoma
• High‑grade serous ovarian cancer
• MET‑driven papillary renal cell carcinoma

Across 154 trials and 56 investigators, the focus is on improving survival and response rates by evaluating novel agents and combination regimens.

Research at the Verona site includes trials aimed at better control of severe asthma with an eosinophilic phenotype and other chronic lung conditions.

• Severe eosinophilic asthma
• Chronic obstructive pulmonary disease
• Idiopathic pulmonary fibrosis
• Bronchiectasis in cystic fibrosis
• Eosinophilic granulomatosis with polyangiitis

The trials aim to reduce medication burden, prevent exacerbations, and assess long‑term safety of emerging biologics.

A series of studies target autoimmune disorders, exploring innovative biologic therapies to modulate immune activity.

• Systemic lupus erythematosus
• IgG4‑related disease
• Chronic spontaneous urticaria
• Rheumatoid arthritis flare management
• Polymyalgia rheumatica

Objectives include improving disease control while monitoring safety and tolerability of new agents.

Investigators are conducting trials on myelofibrosis and related hematologic malignancies, focusing on next‑generation JAK inhibitors and immunotherapies.

• Primary myelofibrosis
• Post‑polycythemia‑vera myelofibrosis
• Myelodysplastic syndromes
• Diffuse large B‑cell lymphoma
• Mantle cell lymphoma

The goal is to achieve durable hematologic responses and reduce transfusion dependence.

The site supports studies on gastrointestinal cancers and inflammatory conditions, testing precision medicines for gastro‑esophageal junction adenocarcinoma and other tumors.

• Metastatic colorectal cancer
• Advanced cholangiocarcinoma
• Gastric adenocarcinoma
• Pancreatic ductal adenocarcinoma
• Crohn’s disease

Research aims to improve survival, manage disease‑related symptoms, and identify predictive biomarkers.

Trials in this therapeutic area address cancers and reproductive health issues, including work on high‑risk non‑muscle invasive bladder cancer.

• High‑risk NMIBC
• Advanced ovarian cancer
• Uterine serous carcinoma
• Endometriosis‑related pain
• Hormone‑receptor positive breast cancer

Studies evaluate immunotherapy, targeted agents, and hormone‑modulating strategies to enhance outcomes.

Research includes rare bone disorders and cancer‑related bone complications, such as osteogenesis imperfecta in pediatric patients.

• Osteogenesis imperfecta in children
• Bone metastases from solid tumors
• Paget disease of bone
• Rheumatoid arthritis joint inflammation
• Upper‑limb spasticity after stroke

The aim is to assess bone‑strengthening agents and functional rehabilitation outcomes.

Studies target neurological conditions, including symptom relief for essential tremor and disease modification in select disorders.

• Essential tremor
• Multiple sclerosis relapse management
• Neuropathic pain in cancer
• CNS involvement in lymphoma
• Neuroendocrine tumors of the lung

Objectives focus on improving quality of life and evaluating novel neuro‑protective therapies.

The Verona research program includes investigations of chronic skin and connective tissue disorders, such as chronic spontaneous urticaria.

• Chronic spontaneous urticaria
• Psoriatic arthritis skin manifestations
• Sjögren’s syndrome
• Systemic sclerosis
• Eosinophilic esophagitis

Trials assess efficacy of biologics and aim to reduce disease activity while enhancing patient‑reported outcomes.